The greatest challenge for those wanting real reform from the health technology assessment review is not policy or methods but managing the bureaucracy and the games it is already playing to secure the outcomes it wants.
An appointment that is just another sign of a process in serious trouble
December 14, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
AI in healthcare and why doing nothing might be the biggest risk
February 5, 2026 - - Latest News -
An effective example of making the case for reform in a status quo-biased system
February 5, 2026 - - Latest News -
Pharmac consults on expanding access to Takeda blood cancer therapy
February 5, 2026 - - Latest News -
GBMA moves to reclaim the reform agenda with a focus on pricing and supply
February 5, 2026 - - Latest News -
Nuclear medicine sector argues for dedicated scheme to unlock cancer therapies
February 4, 2026 - - Latest News -
Pfizer’s once-monthly weight-loss injection delivers strong mid-stage results
February 4, 2026 - - Latest News -
GBMA Summit focuses on access, affordability and security in an uncertain world
February 4, 2026 - - Latest News

